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Chapter II

Obesity and Hyperandrogenism
Amit M. Deokar, Shawn J. Smith,
Amanda J. Goodwin and Hatim A. Omar *
Division of Adolescent Medicine, Department of Pediatrics, University of Kentucky,
Lexington, Kentucky, United States of America

Abstract
This chapter has a two-fold objective. One, it addresses the associatiOn of
hyperandrogenism and obesity and the complex metabolic derangements that are part of
the problem. Clinical management of these co-morbidities is challenging and complex.
Second, this article will aid health care providers with the key features to an early
diagnosis and intervention to decrease the morbidities in the short as well as long term.
Method: Systematic review of articles and information on the topic of interest that were
published in the last 15 years. Conclusion: Obesity and hyperandrogenism are integral
.·parts of Metabolic Syndrome/Polycystic Ovarian Syndrome (PCOS)/Hyperandrogenism,
Insulin resistance, and Acanthosis Nigricans (HAIR-AN). With the childhood obesity
epidemic, the metabolic syndrome and the associated abnormalities are routinely seen in
clinical practice and these have a tremendous economic burden on the society and the
quality of life.

Introduction
Obesity in children and adolescents has increased at an alarming rate in the last two
Over the years, researchers have acquired a better understanding about the
of obesity in metabolic syndrome (MS, previously lmown as metabolic
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Patients with MS have various metabolic abnormalities that can include abnonnal glucose
and insulin ratio, insulin resistance, high blood pressure, altered lipid profile, pro-thrombotic
and pro-inflammatory state. Teenagers with .MS are predisposed to long term morbidities,
such as early coronary mte1y .disease, hepatic; steatosis, type 2 diabetes, and stroke [1] .

~:!~::~:;~~gt~;sa~~~~ ~; ot~~~;ei~~t. ~0r&ger~as a~ .~o percent chance of continuing to be

7

Approximately 17 perce~t of children ag7g 2~ 19 years are considered overweight based
on a survey by}'l"ational Health and Nutritiqn Examination Survey of 2003-2004 [3]. As
noted earlier, the rate of obesityha~ double(iin · ~doles. ce11ts,who are in the 12-19 year age
group [4]. The prevalem:e .o f obese and overweight children may be different depending on
the gender·· · artd~Illn~city. · · Fo~ e~a111ple, · !he ·otesitY .1'(\tes i·~rf . }}}ghet iiJ.l African Americans,
Hispanic Americans, males, and those living in the southem :states [2]. The definition of
obesity varies in adolescents when compared to adults due to different proportion of body fat
in boys and girls at different ages [5]. Body Mass Index (BMI) is a reliable tool to assess
obesity, because it is easy to obtain and correlates well with the bqqyfat [6]. Any adolescent
with a BMI of 30 kg/m2 or 95th percentile for gender and age falls in the overweight
category. They are considered at risk of being overweight if their BMI is between 85th and=
95th percentile. In the US, the economic burden of direct and indirect healthcare cost due to
obesity and co-morbidities is estimated to be well over$ 117 billion annually. As the obesity
rates have doubled and tripled respectively in children and adolescents, so have the health
care costs [7]. This impacts the healthcare burden directly.
Obesity and hyperandrogenism (HA) are strongly associated in patients who have been
diagnosed to have polycystic ovarian syndrome (PCOS)/HA/MS. This article addresses their
relationship with one another and specific management options. A subset of (PCOS) includes
hyperandrogenism, insulin resistance and acanthosis nigricans, abbreviated as HAIR-AN
[8,9]. Historically PCOS was described based on findings of multiple cysts in the ovaries,
irregular or no menstrual periods, and hirsuitism. However, absence of ovarian cysts does not
rule out this syndrome [10]. Women with high androgenlevels have assoCiated HAIR-AN
features in about 5-10 percent of cases [11]. The onset of PCOS/HAIR-AN may occurs in
adolescent years and the diagnosis is likely to be delayed until early adulthood [8,9].

Pathophysiology
As PCOS/HAIR-AN is being studied more over the last two decades, different theories have
been proposed to explain the features of the syndrome, including obesity. The primary
problem in HA appears to be due to an altered hypothalamo-pituatary-ovarian axis. The
anovulation and thus abnormal or absence of menstrual periods is from a persistent
leutenizing hormone (LH) surge and its high concentration in the blood. There is also an
increased GnRH surge as the negative feedback fi-om estrogen and progesterone is ineffective
due to relative hypothalamic insensitivity. The LH surge results in increased production of
androgens. The level of follicle stimulating hormone (FSH) is less when compared to the LH
resulting in decreased enzymatic (aromatase) conversion of androgen to estrogen and thus
anovulation.

Obesity and
Another key association of HA is hyperinsulinsm. This is
resistance, which can result in a hyperglycemic state. The level of sex' .,A,.,"''".,
globulin (SHBG) is decreased due to the high insulin levels and consequently there
in the free testosterone level [8]. Insulin also increases the androgen productio\1. by
stimulating the theca cells [12]. Both hyperinsulinism and HA predispose an ind '
have an athrogenic lipid profile. Total cholesterol, triglycerides (TG) levels are also
Increased activity of the enzyme lipase affects the cholesterol metabolism and could result in
a decreased level of the high density lipoprotein-cholesterol (HDL-C) [13]. Another
postulated mechanism for HAIR-AN is a genetic mutation of the insulin receptor (tyrosine
kinase domain) [9].
Effects ofHA can be multi-fold. Even though increased androgen production in women
is associated with obesity, one study in 2002 by Gapstur et al [14] in obese men have found
to have lower testosterone and dehydroepiandroterone sulfate (DHEAS) levels. High
androgen levels in children and adolescents are linked to precocious puberty, accelerated
bone growth, height, features of PCOS, and are more commonly seen in obese subjects
compared to non-obese. In pre-pubertal obese children the level of DHEAS is often elevated
[14].
Recently, researchers have looked at the effects of proteins like adiponectin, resistin,
leptin, and TNF -a on the fat metabolism, peripheral insulin resistance, and energy
expenditure [15]. Resistin is produced by the mature visceral and subcutaneous adipocytes
and influences insulin sensitivity. Adiponectin and leptin, also secreted fi-om the adipocytes,
have similar roles [16]. A recently published study by Shin et al [17] suggested obesity as an
inflammatory process due to findings of increased levels of C-reactive protein (CRP) and
TNF found in obese children. The adiponectin level was found to be much lower
concentration in these children. Retinol Biding Protein 4 (RBP4) is present in omental and
subcutaneous fat and is expressed more in women with PCOS [18]. The high levels of
androgen and features of metabolic syndrome have shown to normalize in post-menarche
obese adolescents after weight reduction [19].

Diagnostic Criteria
A standard list of the diagnostic criteria for MS in children and adolescents is still lacking.
However, a modified diagnostic criteria for children using the NCEP criteria and data from
the National Health and Nutrition Examination Survey (NHANES, 1988-94) is widely used.
The National Cholesterol Education Program (NCEP) and the Adult Treatment Panel III
(ATP III) include at least 3 of 5 of the following criteria for the diagnosis of MS in
[1,2,20,21].
•
•

Abnmmal lipid panel: Hypertriglyceridemia (> 150 mg/dl) and
(<40mg/dl in males and <50 in females).
High fasting glucose level. Hyperglycemic state is defined as
100 mg/dl or more.
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•

•

Elevated ·blood .pr.f!ssm·~, syst()li£, qia~t()li<:, ()r both using reference ranges. From
example, ..blood pres~we 0 f )-13,5/~.5 ~'11lw-rg; .i~ . 9011.~idered abnormai.
Increased waist ci.J.·cl!IJ1fer~~l9e/apqg~~·~l.. g;i~ll· J3MI . is fairly reliable in assessing
obesity in children... > .> i ·i<' ic .isi iii >
High inslllit1resistance ( cdterio~ it1pl~j!dr~.nJx .\
The World Health Organizatiol1(\}'H("))£ri~~ri~ . required elevated insulin or glucose

•
•
•
•

.·.••.· .· •. · .o·. ·•. .··• .· ·.· ·o.•<·•.··•.· •. f·. ·. the following: [2]
level (> 11 Omg/dl)
<
Abdominal
obesityin a.ddit. . on t·. o·.••·•••.·.·a·. •.·. t·.•· ..•··. •···.••l·.•••.· .e·· .·.• • ·.a·. ·.•••·. ·s.•·•. ·.·•.·.t•.•.·..· .· .· · .w
waist size >94 em or waist to hip s~t~()!()~)-9;1
Triglycerides > 150 mg/dl . orl!l)J, <::;~.$p.ig(gl·
Blood pressure > 140/90rm1ll!g.

•

•

~.·

···t····.. •..•..

HAIR-AN is a clinical diagnosis and includes t
above (9]:

p~l~~1h~,in addition to criteria mentioned
i":·::

Acne, hirsuitism,, ~~~pora1 . bl,l}~'pg, ;i¢m(.)i(.)ffi¢galy, and deepening of VOICe
(suggestive ofhighandrogep.Jf!Yf!D·
b) Acrochordons (skin tags), a.cat1W()~i~t1}$1"lcf~~~(llsll(llly found on the neck, axillae,
and back). These are suggystiye ()fii).§\lHII.Xf!Si§t<lP.Pe and altered hmmonallevels.
a)

<;r!(·t;<:~

Sugg~~~~~:;: WQrkup
Anthropometric measurement, vital,'

,,~~~~~c~JJceinplete history and physical exam

(including genital) is reconunended. ~~et.eil~~ f~~ly,past medical, and medication history
should also be documented. Laboratgt1'/4~~~ <:11,af:i l}l<lY be useful includes, fasting levels of
insulin, glucose (complete metabolic Pel1elit~ ~~§es~ Ji;er .and renal function) , lipid panel,
glucose/insulin ratio, HgAlc, and AMcqnisgll~;e~.Qral glucose tolerance test (2 hour) is
also recommended to document hyperglyc~~t sta.te. One test that has high sensitivity and
specificity is the euglycemic hyperills11li.t1errgp plamp. This may be impractical in a clinical
setting due to the time consumin~a~g potl"lpl~.xeamr·e of the test (9]. A thorough endocrine
evaluation should include thyroid >:flll:i<:tipt1 tests, serum prolactin, DHEA-S, am 17hydroxyprogesterone (17-0HP), sHBqle)'f!l,aed free and total testosterone. IGF-1 level
may be helpful in a suspected growt11h()J.1POp.eproducmg tumor [22].
· In order to establish the diagnosispf~(:JQS, .the presence of multiple ovarian cysts is not
necessary. Likewise, an abdomillal/peJyiq .@tr~sound detection of multiple ovarian cysts does
not confitm that diagnosis either. Q<;:c(lSi()riaUy a computed tomography (CT) or an MRI of
the abdomen/pelvis may be necessary in situations where there are progressive signs of
hyperandrogenism [22].
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Outcome
HAIR-AN subset) in children can lead to
short and long term medical problems. This exhaustive list includes
to the following [6]:

Ju1IJll'-·'"'-·U

Distorted body image and perception
Low self-esteem and depression
Acne
Obesity associated problems like snoring, obstructive sleep apnea, disordered sleep,
gastro esophageal reflux disease (GERD), gall stones, joint pain, exercise
intolerance, features of diabetes, coronary artery disease, and skin changes, etc.
Amenonhea (predisposing to subsequent inadequate bone mineralization) and
possibly infe1tility.

Treatment Options
timeframe for the diagnosis of metabolic syndrome/HAIR-AN to the outcome of the
varies from patient to patient and can be often protracted. A multidisciplinary
is often required to address the metabolic as well as the psychological stressors
with this syndrome. reatment should be geared toward specific metabolic
u .... u ......, as well [6,9,23]. It is important for the healthcare provider to be aware of the
that teenagers may have when it relates to cosmetic appearance. At a psychological
....., .•,..,""P1Hv1.1la1 stage where bodily appearance plays an important role in a teenager 's life,
,. . , ~",,,.related problems such as acanthosis nigricans, acne, and hirsuitism may be quite
~ . . .---~·eo [22]. This can affect their self-esteem directly. Health care providers should have a
.,, •·u"'""'"1u for refening these teenagers to counseling services.
c('l.a,tm~nt

compliance can play a big role with this approach, it is considered one of the most
and successful mode of treatment in obese patients, who also have HA [22). Weight
dramatically improve the ovarian function and decrease the levels of androgens [24].
dietary changes such as caloric restriction of carbohydrates or fat with increased
intake ]).ave been previously studied. There is no sufficient data available if restrictio11,
is better than that of fat intake. It is therefore prudent to use the
,-···-·u.. or nutritionist who can work with obese/overweight individuals.

Mf11vu,"'u
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treatment may include a
androgens, insulin-sensitizing
and complementary and
•u•••u·u·"~"H·'u'·'"" J approach, psychological

Biguanide: Metformin
B drug, has
point, Metfonnin interten::s JiVitb tb<
and decreases
gluconeogenesis. It
muscles, by · activating
enhancing the glucose
also acts against the gl
obesity associated with HA. Due to
in the free and total
beneficial effect on ovulation,
As obesity is strongly ....,.,v...,,......,.u
has an added benefit of being

a pregnancy category
(DM). From a glycemic stand
l1t¢p,;*>P:Yi.e • rQJttQ.I~b~mcirilll respiratory oxidative process
not a complete blockade of
in tissues such as the skeletal
on the insulin receptors and
is also on the adipocytes. It
Metformin is particularly useful in
there is a consequent decrease
estradiol level [25]. This has a
""Vt!f'I-''W~·'YY"f~~,uH~·

morbidity and mortality, metformin
shown to decrease the free fatty
. It may also help lower the total
(VLDL-C), low density
lipoprotein cholesterol (HDL-

lipoprotein cholesterol
C). It also lowers the platelet agJ~re,g~ti9n 1:\r\g. ;~q~t~slon,
plasminogen inhibitor 1 and von
[26]. It can induce vascular uo•a"-'~'f~'l.l '~l.l~'\~0"!"'~'-' ~~gt

with an addition of drosperinone
fat [27].
gastrointestinal symptoms such as
nausea, flatulence and uu•Lau''-'"· ""'''"' .Lna.v LJ" ''"'u'-'"~''u by taking it with food. Treatment may
be started with a single daily
a lowest possible dose. It may then be
re,CbJ:nplertde:d to go over the maximum dosage of
increased to a twice daily dose.
2.25 grams/day [25]. One must
potential toxicity from metfromin that
includes lactic acidosis in rare si ua••v"·"· 1\,lf.>tf'n·r rn; ... is fairly safe for the mother and baby
during pregnancy and lactation [28].
Thiazolidinediones: Rosiglitazone is an insulin sensitizing agent, whose action on the
peroxisome proliferator-activated receptor (PP AR ) on the adipocytes improves glucose
transport into the cell by increasing the adiponectin secretion [29]. In studies done earlier on
overweight women with PCOS, there was a decrease in the insulin resistance and return of
ovulation as indicated by regular menses. The SHBG level also shows an increase that helps
,.,.,..,...~,.....,.,,...abdominal
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ovulation. Some of the side effects include weight gain
Ll">'-''"IJ'J'u'" individuals [30].

ulation of the Hormonal/ Androgen Imbalance and Use of Oral
aceptives
bitih control pills (BCP's) are the cornerstone in the treatment of HA. Their
,,, 10 ..,u,uu,~u• of action includes the following:
Increase the SHBG production and level: This allows a reduction of free
testosterone.
Suppress LH: Decreases androgen production from the ovaries.
Anti-minerelocmiicoid activity: Certain progestins such as Drosperinone have low
androgenic activity and are generally preferred in HA. The brand name
contraceptives Yasmin® and Otiho-Tri-Cyclen® contain Drosperinone.
effects of combination BCP's include normalization of menses and a decrease in acne
hirsuitism [22]. In addition to the above, other phannacologic agents have been tried in
states are cyproterone acetate, :finastreride, glucocorticoid, such as prednisone (patients
late onset congential adrenal hyperplasia (CAH) having PCOS features), and

Surgery: A decrease in obesity-related morbidity has been well documented in
that have undergone Roux-en-Y gastric bypass surgery. Although this is an
procedure that has been evaluated mostly in morbidly obese adults, the guidelines
conservative for the adolescent population. Morbidly obese teenagers, who have
the non-surgical approach may be considered for a gastric bypass surgery. Other
2
" ,..,.,..... awuu" in addition to the above includes a BMI of 40 kg/m or more, physical and
"'u''"'"'-'""" co morbidities from obesity [31]. Bariatric surgery intended to result in weight
can positively impact obesity, PCOS, and reverse anovulation. The risks from obesity
pregnancy in morbidly obese teens is also decreased by the procedure [31]. A 1 to 2
post operatively for becoming pregnant is usually recommended. As there can be
complications from this surgical procedure, careful multidisciplinary evaluation for
.,.....,,. ....,~--·for surgery is needed.

plementary and Alternative Medicine
approaches in the treatment of PCOS have been
of side effects from the traditional medical and surgical tre:atn1en:t, J·esc~ar,b!J.~~!.'s, /
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looked at the benefits pfaq4pu:qctur~, l:lj:):<tclitionaLfonn oLChinese medicine. Acupuncture
has been shown to
in lowering of the increased
sympathetic ton~
the technique of
acupuncture c(ln
ol and LH levels [32].
neuro-endocrinal
As a result, its
Other fonns of
endogenous systems can
altemative medicine such as nuJlnt:•up<ii!l:Y>
PHJL11-"'"u'"u•"• and hypnotherapy
have been tried to treat obesity in
not vety convincing [33].

The CDC (Center for Disease
ofNutrition and Physical
Activity (DNPA) and the health
established the Nutrition and
Physical Activity Program to Pr~~velif<oti'esiit\Ji·''aiil:ti !)tf[gr icltron· Diseases (NPAO) since
1999 using the social ecological
are encouraged to contact
their individual health departments
where available.

Metabolic syndrome,
abnormalities that have a great
The diagnosis is often late and
problems. The following kyy
of HAIMS/PCOS and appropriate

integral part of complex metabolic
general well-being of an individual.
ec<mcnnJIC burden from obesity related
provider with the timely diagnosis

•

Healthcare provider

•

Utilizing diagnostic gitG~~ag '~·~~~~~r+~~M~L§~~ diagnosis of PCOS/HA/MS. One may
diagnostic criteria.
refer to the NCEP,
A complete history,
family, past, and medications.
Complete physical
diagnosis of HAIR-AN is clinical.
Laboratmy and
list includes fasting insulin, glucose
(complete
liver and renal function), lipid panel,
glucose/insulin
level. Oral glucose tolerance test (2
hour) , thyroid function
prolactin, DHEA-S, am 17-hydroxyprogesterone
(17-0HP), SHBG level,
and total testosterone, IGF-1 level are also
recommended.
Management that inclgdes meifical, . surgical, lifestyle modification techniques, and
appropriate referr~l~ )8 pther sub-specialty providers for addressing associated co
morbidities. Keepi:qg ip miHci that some patients may desire to utilize altemative and
complimentary medicine options as well.

•
•
•

•

childhood and adolescence.

Obesity and Hyperandrogenism
Multidisciplinary approach that includes, the primary care
social worker, nutritionist, and counselor/psychologist.

References
Kranz S, Mahood LJ, Wagstaff DA. Diagnostic criteria patterns of US children with
metabolic syndrome: NHANES 1999-2002. Nutrition J 2007;6:38.
Strasburger VC, Bravetman PK, Rogers PD, Holland-Hall CM. Adolescent medicine:
A handbook for primary care, 1st ed. Philadelphia, PA: Lippincott Williams Wilkins,
2005.
CDC. Prevalence of ove1weight among children and adolescents: United States, 20032004. 2007 [cited 2008 05/16/2008]; Health E-Stat. National Center for Health
Statistics. Centers for Disease Control.]. Available from: http://www.cdc.gov/
nchs/products/pubs/pubd/hestats/ overweight/overwght_child_03 .htm
National Association of Children's Hospitals and Related Institutions (NACHRI).
Childhood Obesity Statistics and Facts. 2007 [cited 2008 05/ 16/2008]; Available from:
http://www .childrenshospitals.net/AM/Template.cfm?Section=Homepage&TEMPLAT
E=/CM/ContentDisplay.cfm&CONTENTID=34357
CDC. Defining overweight and obesity, 2007 [cited 2008 05/14/2008]; Defmition for
children and teens]. Available from: http://www.cdc.gov/nccdphp/dnpa/obesity/
Krebs NF, Himes JH, Jacobson D, Nicklas TA, Guilday P, Styne D. Assessment of
and adolescent overweight and obesity. Pediatrics 2007;120(Suppl4):Sl93-228.
Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab
;89(6):2522-5.
McCartney CR, Prendergast KA, Chhabra S, Eagleson CA, Y oo R, Chang RJ, et al.
The association of obesity and hyperandrogenernia during the pubertal transition in
girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J
· Endocrinol Metab 2006;91(5):1714-22.
KM, Omar HA. Androgen excess disorders in women: the severe insulinresistant hyperandrogenic syndrome, HAIR-AN. ScientificWorldJournal 2006;6:1161.
"'·•UA.J'"'" I Khan DMK. Polycystic ovarian syndrome. 2006 [cited 2008 05114/2008];
v cu.• au'" from: http:/ /www.emedicine.com/med/topic2173 .htm
RL, Hornstein MD. Hyperinsulinemia and ovarian hyperandrogenism. Cause
effect. Endocrinol Metab Clin North Am 1988;17(4):685-703.
CR, Blank SK, Prendergast KA, Chhabra S, Eagleson CA, Helm KD, etal.
and sex steroid changes across puberty: evidence for
<n~rperantOr<)ge:neJmla in pre- and early pube1ial obese girls. J Clin Endocrinollv~~'<•av : <i·
all<:enlbm·g: 0, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie
esterveld EH, et al. A more atherogenic serum lipoprotein

26

[14]

[15]
[16]

[17]

[18]
[19]

[20]

[21]

[22]
[23]

[24]

[25]
[26]
[27]

[28]

Obesity and Hyperandrogenism
women with polycystic ovary syndr01ll<;!:.a case-control study. J Clin Endocrinol Metab
2008;93(2}:47Qdj.
Gapstur SM, GaiLIL PH, Kopp :t;>, Colangelo L, Longcope C, Liu K. Serum androgen
concentrations iri Y?llllg; .Jl!~g: a longitudinal anaJ~~is of associations with age, obesity,
and race. The C~Jf\' i11ll:lle hormone stud,Y. \yancer Epidemiol Biomarkers Prev
2002;11(10 Pt 1):1041,..7.
Zou CC, Liang L,<I-Jppgcl'·' ~eJationship betwe.§~ iJ1slJ]iriJ'<;!Sistance and serum levels of
adippnectit;l ~t;IQ resistin with.clliiclll()Od Q.Q5~ity.Jlldiall J?ediatrics 2007; 44(4): 2 7 5-9.
1let;~cll<;!fJ; . ]?}ac~\V<;!llSc,M<;!I.lta \~II, WJ;:titty.J:E,Ru.ssyll}j,Sprokin Y, et al. The levels
of leptin, adiponectiri, /and resis~in in noril}al weigl.lt, ()verweight, and obese pregnant
women with and without preeclampsia. Am J OqstetGynecol2005;193(3 Pt 2):979-83.
ShinN, Kim SY, Jeung MJ, Eun SH, Woo{}\M,iiJ'"gon§X; et al. Serum adiponectin,
C-reactive protein and TNF-alpha levels in obese Korean children. J Pediatr
Endocrinol Metab 2008 ;21(1):23-9.
Stanley T, Misra M. Polycystic ovary syndrome in obese adolescents. Cun Opin
Endocririol Diabetes Obes 2008;15(1):30-6.
Wabitsch M, Hauner H, Heinze E, Bockmann A, Benz R, Mayer H, et al. Body fat
distribution and steroid honnone concentrations in obese adolescent girls before and
after weight reduction. J Clin Endocrinol Me tab 1995 ;80( 12): 3469~ 75.
de Ferranti SD, Gauvreau K, Ludwig DS, Neufeld EJ, Newburger JW, Rifai N.
Prevalence of the metabolic syndrome in American adolescents: Findings from the
Third National Health and Nutrition Examination Survey. Circulation 2004;
110(16):2494-7.
CookS, Weitzman M, A11inger P, Nguyen M,i;pietrWH· Prevalence of a metabolic
syndrome phen?type in ad()lescents: Finding~ fr9111the third National Health and
Nutrition Examination Survey, 1988-1994 ... Arch Pediatr Adolesc Med 2003;
157(8):821-7.
Harwood K, Vuguin P, DiMartino~NI:lfclt .J, Current approaches to the diagnosis and
treatment of polycystic ovarian SY1ldf9~ll,~ iJ:l youth. Horm Res 2007; 68( 5) :209-17.
McClanahan KK, Omar HA. Navigating adolescence with a chronic health condition: a
perspective on the psychological effects of HAIR-AN syndrome on adolescent girls.
ScientificWorldJoumal 2006;6: 1350-8.
Huber-Buchholz MM, Carey DG, Nonnan RJ. Restoration of reproductive potential by
lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity
and luteinizing hormone. J Clin Endocrinol Metab 1999;84(4): 1470-4.
K.irpichnikov D, McFarlane SI, S()W¢rs JR. Metforrnin: an update. Ann Intern Med
2002; 137(1 ):25-33.
Bailey CJ. Metformin--an update. Gen Pharmacoll993;24(6):1299-309.
Ibanez L, De Zegher F. Flutamide-metformin plus an oral contraceptive (OC) for
young women with polycystic ovary syndrome : switch from third- to fourth-generation
OC reduces body adiposity. HumReprod 2004;19(8) :1725-7.
Goldenberg N, Glueck C. Medical therapy in women with polycystic ovarian
syndrome before and during pregnancy and lactation. Minerva Ginecol 2008;60(1):6375.

Obesity and Hyperandrogenism
Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen
Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of
resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur
J Endocrinol2007;156(2):263-9.
Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in
patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis
ofrandornised clinical trials. Lancet 2007;370(9593):1129-36.
Miller RJ, Xanthakos SA, Hillard PJ, Inge TH. Bariatric surgery and adolescent
gynecology. Cun Opin Obstet Gynecol2007;19(5):427-33.
Stener-Victorin E, Jedel E, Manneras L. Acupuncture in polycystic ovary syndrome:
cunent experimental and clinical evidence. J Neuroendocrinol2008;20(3):290-8.
Pittler MH, Ernst E. Complementary therapies for reducing body weight: a systematic
review. Int Journal Obes 2005;29(9): 1030-8.
[34] Hamre R, et al. CDC's state-based nutrition and physical activity program to prevent
obesity and other chronic diseases. July 2006 January 17, 2008 [cited 2008 06/24/08);
Available
from:
http://www. cdc. gov/nccdphp/dnpa/ obesityI state_pro grams/pdf/
NPAO_Perfonnance_Report_2005.pdf

